LAS VEGAS, July 30, 2020 /PRNewswire/ -- JanOne Inc.
(NASDAQ:JAN), a company focused on finding treatments for
conditions that cause severe pain and bringing to market drugs and
therapies with non-addictive pain-relieving properties has added
two members to its impressive scientific advisory board.
John Cooke, MD, PhD will contribute
his esteemed depth of vascular expertise to help guide the success
of our clinical therapeutic for the treatment of PAD. Alan Kaye, MD, PhD, is an internationally
renowned anesthesiologist and pharmacologist whose pain management
research and clinical formulation expertise will play a critical
role in advancing our efforts to bring non-addictive pain solutions
"I was impressed with JanOne's progress towards the next phase
of trials for its Peripheral Artery Disease (PAD) treatment.
PAD affects over 8.5 million people in this country, and our
medical treatments for relieving the symptoms of PAD are
limited. I look forward to working with my other accomplished
colleagues on the JanOne scientific advisory board," commented Dr.
Dr. Kaye adds, "Finding answer to treating pain and doing so
with formulations without addictive properties is an area of
research that has garnered my attention for over twenty years.
JanOne's commitment to finding answers to treat diseases that cause
chronic pain in a manner to reduce the need for opioid
prescriptions is particularly appealing. I am honored to be a part
of the team."
Dr. Cooke's impressive career spans over 30 years with
significant achievements in cardiovascular medicine and research.
Receiving his doctorate from Wayne State
University School of Medicine, he trained at the Mayo Clinic
in cardiology and vascular medicine where he went on to obtain his
PhD in physiology. Subsequently he was an assistant professor at
Harvard Medical School and served in
leadership roles at Stanford
University's vascular biology and medicine program and
became associate director of the Stanford Cardiovascular Institute.
Having published over 500 papers and reviews, an inventor on over
30 patents and with over 30,000 citations in vascular medicine and
biology to his name, Dr. Cooke currently serves as the chairman for
the Department of Cardiovascular Sciences, and Director of the
Center for Cardiovascular Regeneration at Houston Methodist
Dr. Kaye has a long, well-regarded professional background that
includes serving in the United
States Army Medical Reserves as a captain for seven years
and five years as major. Earning his doctorate from the
University of Arizona Medical School
and a PhD in pharmacology from Tulane
School of Medicine, Dr. Kaye also completed a pain
fellowship at Texas Tech University Health
Sciences Center. Today, his expertise can be attributed to
over 800 publications and he is the author of over 40 books, many
related to pain management. Dr. Kaye brings significant
clinical pain formulation expertise, most recently assisting with
the formulation of sustained release gabapentin for FDA approval.
He received the Academic Achievement Award from the American
Society of Interventional Pain Physicians in 2016.
"Drs. Cooke and Kaye reflect the outstanding quality of medical
proficiency and clinical experience we know is necessary for us to
broaden our clinical pipeline. We are privileged to have both of
them on our scientific advisory board" remarked Tony Isaac, JanOne's chief executive
JanOne is a unique NASDAQ-listed
company that is focused on bringing medications to market to treat
diseases that cause severe pain in an effort to reduce the need for
prescriptions opioids often used to treat disease associated pain.
The company is also exploring solutions for non-addictive pain
medications. The lead candidate is for treating peripheral artery
disease (PAD), a condition that affects over 8.5 million Americans,
with plans currently underway for phase 2b trials. JanOne is currently dedicated to
funding resources toward innovation, technology, and education for
PAD and neuropathic pain. The company continues to operate its
legacy businesses, ARCA Recycling and GeoTraq, under their current
brand names, but has recently announced both are undergoing a
review to determine appropriate strategic alternatives in an effort
to focus on it biopharma interests. ARCA Recycling
provides turnkey recycling and replacement services for utilities
and other sponsors of energy efficiency programs. GeoTraq engages
in the development, design and, ultimately, the company expects,
sale of Mobile IoT modules. Please visit www.janone.com for
View original content to download